Company intelligence / Profile preview

Tenvie Therapeutics

South San Francisco, California, United Statestenvie.com ↗

Ownership: Private
Employees: ~14
Development stage: Other

Overview

Tenvie's most advanced programs are in IND-enabling studies, targeting NLRP3 and SARM1. Additional preclinical programs target neuroprotective pathways such as TRPML1 and TMEM175. The company has not yet reported clinical results but aims to move multiple assets into clinical trials with its recent $200 million funding round

Therapeutic areas: OphthalmologyCardiovascularNeurology
Modalities: Small molecules (brain-penetrant and peripherally restricted)
Industry: Biotech

Drug pipeline

2 assets

TNV108

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed as of launch. Initial pipeline includes assets acquired from Denali Therapeutics.

Beyond the preview

Go deeper on Tenvie Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenvie Therapeutics.

Explore the full profile